Catheter Connections' vascular access disinfecting cap gets US clearance
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for DualCap, a device developed by Catheter Connections (Salt Lake City, Utah) to disinfect IV access points, the needleless injection site (NIS) and the male luer – a type of connector fitting – at the end of the IV tubing. Patients contract catheter-related bloodstream infections when microbes enter the bloodstream in one of two ways. The less prevalent route is from the skin at the catheter insertion site. The more common route is intraluminal contamination, when the two primary IV access points, the NIS and the male luer, become contaminated. There are nearly 500,000 cases every year with a 12-25% mortality rate in the US. DualCap will go on sale in the US in the second half of 2010.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.